Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s IPO and Biotech Market Recovery

Reuters reported that clinical-stage biotech Kardigan is targeting a valuation of up to $1.4 billion in its U.S. IPO, with plans to raise as much as $373.3 million. The Princeton, New Jersey-based company plans to list on Nasdaq under the ticker “KARD” and use proceeds to advance three late-stage cardiovascular drug candidates.

IPOX® Associate Lukas Muehlbauer was quoted in the article on the improving environment for biotech IPOs. He noted that recent healthcare IPO activity points to renewed investor interest, while also emphasizing that the market remains selective and focused on companies with clinical progress and clearer paths toward FDA approval.

“We have seen a clear uptick in biotech IPOs in recent months, with healthcare IPO activity already surpassing last year's deal flow, which shows that the IPO window for the sector is open again,” said IPOX Research Associate Lukas Muehlbauer.

Read the full article by Prakhar Srivastava on Reuters: Heart drug developer Kardigan targets $1.4 billion valuation in US IPO